The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Qiliqiangxin · traditional Chinese medicine · Heart failure with reduced ejection fraction · Heart failure with reduced ejection fraction · Natriuretic peptides · Left ventricular ejection fraction · Randomized controlled trial · Double-blind randomized controlled trial · Placebo-controlled trial · Heart failure hospitalization · Cardiovascular death · Composite Endpoint · Hazard ratio · Guideline-Directed Medical Therapy · All-Cause Mortality · Adverse events · Clinical outcomes · Multicenter trial · Cardiovascular death · Heart failure hospitalization
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459